Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

35.67 +0.05 (+0.14%)
Streaming Delayed Price Updated: 9:35 AM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX: good value for what you're paying.
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma's Earnings Outlook
 
Via Benzinga
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Royalty Pharma Reports Third Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Why PTC Therapeutics Soared 15% Higher Today
The company scored a $1 billion upfront payment for expanding a commercial partnership. 
Via The Motley Fool
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Royalty Pharma Reports Second Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit. 
Via The Motley Fool
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Third Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 129 stocks made new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.